
V2ACT Therapeutics(TM), LLC Announces FDA Clearance of an IND Application to proceed with a Phase 1/2a Study of V2ACT for the Treatment of Pancreatic Cancer
– V2ACT Therapeutics(TM), LLC is a joint venture of Genelux Corporation and TVAX Biomedical, Inc.- V2ACT is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic immunotherapy) and V-ACT (vaccine-enhanced adoptive cell therapy).- V2ACT… […]